RELAPSING MULTIPLE SCLEROSIS (RMS)
Clinical trials for RELAPSING MULTIPLE SCLEROSIS (RMS) explained in plain language.
Never miss a new study
Get alerted when new RELAPSING MULTIPLE SCLEROSIS (RMS) trials appear
Sign up with your email to follow new studies for RELAPSING MULTIPLE SCLEROSIS (RMS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New dosing plan for MS drug aims to improve convenience
Disease control OngoingThis study tests a new maintenance dosing schedule for ofatumumab, a drug used to control relapsing multiple sclerosis (MS). Researchers want to see if the new schedule works as well as the current one in terms of drug levels in the blood, safety, and side effects. The study invo…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS (RMS)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:52 UTC
-
MS drug ublituximab tested for Long-Term safety in 1,100 patients
Disease control OngoingThis study looks at the long-term safety and effectiveness of the drug ublituximab for people with relapsing multiple sclerosis (RMS). About 1,100 participants who completed earlier studies will continue treatment. The main goal is to track how many relapses occur each year while…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS (RMS)
Phase: PHASE3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated May 20, 2026 11:54 UTC